Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar 11;15:2207. doi: 10.1038/s41467-024-46600-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a Changes in protein turnover rates between carfilzomib vs. normal iPSC-CMs across selected cellular compartments; ∙: P < 0.1; *: <0.05; ** <0.01; Mann-Whitney test (two-sided) with Benjamini-Hochberg multiple-testing correction. Dashed line: 1:1 ratio; point: median ratio; range: median ± MAD/median of ratios; n=number of peptide observations (parenthesis) over 2 biologically independent samples per gorup. Source data are provided as a Source Data file. b Kinetic curve representations of proteins with accelerated temporal kinetics in carfilzomib, including PSMC2 which corresponds to the ratio in panel A, as well as additional ERAD proteins and chaperones; gray: normal iPSC-CM; green: carfilzomib. Point: best-fit k; line: the first-order kinetic curve of k; bands: fitting s.e. c Kinetic curve representations of slowdown of protein kinetics in DSP, DMD, MYH6, and MYH7, corresponding to the ratios in panel a. Point: best-fit k; line: first-order kinetic curve of k; bands: fitting s.e. d, e Spatial map (PC1 vs. PC2) and ultracentrifugation fraction profiles of d. BAG3 and e. PSME4 in normal and carfilzomib-treated human iPSC-CM, showing a likely differential localisation in conjunction with kinetics changes. White-filled circles: light and heavy BAG3 or PSME4 in each plot. The kinetic curves of BAG3 and PSME4 are in panel b. Numbers at arrows correspond to BANDLE differential localization (DL) probability.